Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CEACAM1
REST API REST API
Homo sapiens
CEACAM1 is differentially expressed in 323 experiments: 180 organism parts: liver, bone marrow, ... (178 more);, 219 disease states: normal, breast carcinoma, ... (217 more);, 113 cell types 478 cell lines 43 compound treatments and 74 other conditions.
Synonyms CD66a, BGP1, BGP
Gene Ontology Term angiogenesis, cell migration, plasma membrane, protein binding, homophilic cell adhesion, extracellular region, membrane fraction, integrin-mediated signaling pathway, molecular_function, integral to plasma membrane, integral to membrane
InterPro Term Ig_V-set, Ig_sub, Immunoglobulin, Ig-like, Ig_sub2, Ig_I-set
UniProt Accession P13688, P06731, E7ET43, E7EUB1
Search EB-eye ENSG00000079385
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, ... (36 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
SW480
4
E-MEXP-1014, E-MTAB-37, E-GEOD-18005, E-GEOD-2509
A549
2
E-GEOD-3202, E-GEOD-6013
KG1
2
E-MTAB-37, E-GEOD-24147
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
472 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (56 experiments)

Factor Value U/D Experiments
stromal cell
4
E-MEXP-2034, E-MEXP-1327, E-GEOD-10797, E-GEOD-3998
CD8+ T cell
1
3
E-GEOD-6740, E-GEOD-19069, E-AFMX-5, E-MTAB-25
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-TABM-145, E-AFMX-5
adipocyte
2
E-AFMX-5, E-TABM-145
epithelial cell
1
2
E-MEXP-2034, E-MEXP-1327, E-GEOD-10797
107 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (69 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-37, E-GEOD-3726, E-MTAB-62, E-MTAB-57
lung adenocarcinoma
4
E-MTAB-62, E-MTAB-37, E-GEOD-2514, E-MEXP-231
cervical carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-5823
control
3
E-GEOD-8121, E-GEOD-16363, E-GEOD-20602
head and neck squamous cell carcinoma
3
E-GEOD-6631, E-GEOD-2379, E-MTAB-62
neuroblastoma
2
E-MTAB-62, E-MTAB-37
213 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-5542, E-GEOD-3720, ... (27 experiments)

Factor Value U/D Experiments
none
3
8
E-GEOD-5542, E-GEOD-2803, E-GEOD-7400, E-GEOD-412, E-GEOD-5824, ... (11 experiments)
filtered air
1
E-TABM-127
phoshate buffered saline
1
E-GEOD-3720
nocodazole
1
E-GEOD-5258
pergolide methanesulfonate
1
E-GEOD-995
Cxcl12
1
1
E-GEOD-7307
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-2191, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (10 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-17385, E-MTAB-108, E-GEOD-361, ... (7 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-17476, E-GEOD-2466, E-GEOD-20115, E-GEOD-18005, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MEXP-2069, E-TABM-26, E-TABM-15, E-TABM-118, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-MEXP-561, E-GEOD-980, E-GEOD-17400

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-22541, E-GEOD-7307, E-GEOD-19188 ... (5 experiments)

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

Processing time: 0.512 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM